Company Overview of F. Hoffmann-La Roche Ltd
F. Hoffmann-La Roche Ltd. provides in-vitro diagnostics and drugs for cancer and transplantation. The company specializes in medicines for oncology, virology, inflammation, metabolism, CNS, clinical chemistry, immunology, urinalysis, blood screening, genetics, infectious diseases, and microbiology. Its products include cancer treatments, such as Avastin, Herceptin, and MabThera that are also effective in the treatment of rheumatoid arthritis, anemia, and osteoporosis. The company also researches, develops, and produces molecular diagnostic reagents, test systems, and test kits. In addition, it provides automated instruments, software, consumables, and IT solutions used in in-vitro diagnostic...
Founded in 1896
Key Executives for F. Hoffmann-La Roche Ltd
Chief Executive Officer of Roche Group
Compensation as of Fiscal Year 2015.
F. Hoffmann-La Roche Ltd Key Developments
F. Hoffmann-La Roche AG Reports Earnings Results for the Year Ended December 31, 2015
Jan 28 16
F. Hoffmann-La Roche AG reported earnings results for the year ended December 31, 2015. For the period the company announced net income attributable to shareholders was CHF 8.86 billion, or CHF 10.28 per diluted share, compared to CHF 9.33 billion, or CHF 10.81 per diluted share, for the year ended December 31, 2014. Sales was CHF 48.14 billion, compared to CHF 47.46 billion for the year ended December 31, 2014. Operating profit was CHF 13.82 billion, compared to CHF 14.09 billion for the year ended December 31, 2014. Profit before taxes was CHF 11.99 billion, compared to CHF 12.51 billion for the year ended December 31, 2014.
F Hoffmann-La Roche and Glenmark Pharmaceuticals Settle Patent Litigation on Cancer Therapy
Jan 2 16
F Hoffmann-La Roche and Glenmark Pharmaceuticals have settled a patent litigation on lung cancer therapy erlotinib hydrochloride out of court. Roche received the patent in India for erlotinib hydrochloride, which is sold under the brand name 'Tarceva', on February 23, 2007. But the drug maker got engaged in patent disputes with Cipla over Tarceva. Glenmark and Roche ensured that they had reached an agreement over existing patent disputes related to the anti-cancer drug Erlotinib Hydrochloride, according to a joint statement by the two companies. As part of the contract, the companies had ceased all significant patent litigation on that product and Glenmark had approved the patent rights of the Swiss company. Tarceva is developed and commercialized by Astellas Pharma US in collaboration with Genetech, Chugai and Roche in the United States, Japan and rest of the world, respectively.
F. Hoffmann-La Roche Ltd Presents at 8th Annual Biotech Showcase Investor Conference 2016, Jan-12-2016 08:00 AM
Dec 8 15
F. Hoffmann-La Roche Ltd Presents at 8th Annual Biotech Showcase Investor Conference 2016, Jan-12-2016 08:00 AM. Venue: Parc 55 San Francisco, 55 Cyril Magnin Street, San Francisco, CA 94102, United States. Speakers: Simon Meier, Investment Director.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|